Circovirus Vaccine Receives Four-Month Duration of Immunity Approval
US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) has announced that the U.S. Animal and Plant Health Inspection Service has approved a duration of immunity (DOI) claim for Ingelvac® CircoFLEX™ of at least four months for porcine circovirus type 2 (PCV2), the primary pathogen for porcine circovirus associated disease (PCVAD).